Acumen Pharmaceuticals (ABOS) Profit After Tax (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Profit After Tax data on file, last reported at -$20.8 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 27.61% year-over-year to -$20.8 million; the trailing twelve-month figure through Mar 2026 stood at -$113.3 million (up 2.99% YoY), and the FY2025 full-year result was -$121.2 million, down 18.03% from the prior year.
• Profit After Tax climbed to -$20.8 million in Q1 2026, from -$25.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$9.7 million in Q1 2022 to a low of -$40.9 million in Q2 2025.
• A 5-year average of -$20.1 million and a median of -$16.5 million in 2023 frame the typical range for Profit After Tax.
• Peak annual rise in Profit After Tax reached 83.46% in 2022, while the deepest fall reached 174.47% in 2022.
• Tracing ABOS's Profit After Tax over 5 years: stood at -$12.9 million in 2022, then slipped by 28.22% to -$16.5 million in 2023, then tumbled by 128.65% to -$37.7 million in 2024, then surged by 33.29% to -$25.2 million in 2025, then grew by 17.35% to -$20.8 million in 2026.
• Business Quant data shows ABOS's Profit After Tax at -$20.8 million in Q1 2026, -$25.2 million in Q4 2025, and -$26.4 million in Q3 2025.